세계의 희귀질환 치료 시장 : 장래 예측 - 약제 유형별, 치료 유형별, 투여 경로별, 치료 영역별, 유통 채널별, 최종 사용자별, 지역별 분석(-2032년)

According to Stratistics MRC, the Global Rare Disease Treatment Market is accounted for $245.6 billion in 2025 and is expected to reach $599.7 billion by 2032 growing at a CAGR of 13.6% during the forecast period. Rare disease treatment refers to the medical care, therapies, and interventions designed to diagnose, manage, and alleviate symptoms of rare diseases-conditions that affect a small percentage of the population, typically fewer than 1 in 2,000 people. These treatments often involve specialized drugs known as orphan drugs, gene therapies, enzyme replacement therapies, and precision medicine approaches. Because rare diseases are diverse and complex, treatment development requires significant research, innovation, and collaboration among healthcare providers, researchers, and pharmaceutical companies. Effective rare disease treatments aim to improve patients' quality of life, slow disease progression, and, in some cases, offer potential cures.

Market Dynamics:

Driver:

Advances in genomics & precision medicine

Researchers are using whole genome sequencing and transcriptomics to identify disease-causing mutations and molecular pathways. Pharmaceutical companies are investing in orphan drug pipelines that address previously untreatable conditions. Integration with AI and bioinformatics is improving diagnostic accuracy and patient stratification. Personalized treatment protocols are gaining traction across oncology, neurology, and metabolic disorders. These capabilities are propelling innovation and clinical translation across rare disease segments.

Restraint:

Very high therapy development & manufacturing costs

Many therapies require complex biologics, cell engineering, or gene editing platforms that are expensive to produce and validate. Clinical trials for rare diseases often involve small patient populations, increasing per-patient costs and regulatory burden. Reimbursement frameworks remain fragmented across regions, especially for one-time curative therapies. Manufacturing infrastructure for personalized and low-volume treatments is still evolving. These financial and operational constraints continue to hinder equitable access and commercial viability.

Opportunity:

Strong patient advocacy & better diagnosis

Advocacy groups are driving research agendas, supporting trial recruitment, and influencing regulatory pathways. Public campaigns and newborn screening programs are improving early detection and intervention. Governments are launching rare disease registries and national strategies to coordinate care and research. Investment in diagnostic platforms and clinical genomics is expanding access to molecular testing. These developments are fostering long-term growth across therapeutic innovation and care delivery.

Threat:

Supply-chain & specialized care delivery constraints

Many therapies require cold-chain logistics, specialized infusion centers, and trained personnel for administration and monitoring. Geographic disparities in infrastructure and expertise limit access in rural and underserved regions. Regulatory delays and manufacturing bottlenecks can disrupt availability and continuity of care. Coordination across multidisciplinary teams and care settings remains complex and resource-intensive. These challenges continue to hamper scalability and patient outcomes across rare disease ecosystems.

Covid-19 Impact:

The pandemic disrupted clinical trials, diagnostics, and therapy access for rare disease patients worldwide. Lockdowns and resource reallocation delayed treatment schedules and research timelines. However, post-pandemic recovery strategies have emphasized resilience and digital transformation in rare disease care. Telemedicine, remote monitoring, and decentralized trials gained traction across patient communities. Public awareness of health equity and unmet medical needs increased during the crisis. These shifts are accelerating investment in infrastructure, innovation, and policy reform for rare disease treatment.

The oncology segment is expected to be the largest during the forecast period

The oncology segment is expected to account for the largest market share during the forecast period due to the high prevalence of rare cancers and the availability of targeted therapies. Precision oncology platforms are enabling mutation-specific treatments for rare hematologic and solid tumours. Integration with companion diagnostics and biomarker testing is improving treatment selection and outcomes. Pharmaceutical firms are launching orphan-designated oncology drugs with accelerated approval pathways. Investment in immune therapies and cell-based treatments is rising across rare cancer indications.

The gene therapies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the gene therapies segment is predicted to witness the highest growth rate as curative approaches gain traction across monogenic and ultra-rare conditions. Developers are using viral vectors, CRISPR, and base editing technologies to correct genetic defects at the source. Regulatory bodies are offering expedited review and conditional approvals for breakthrough gene therapies. Investment in manufacturing scale-up and delivery platforms is improving readiness and affordability. Partnerships between biotech firms, hospitals, and payers are supporting access and reimbursement models. These dynamics are accelerating growth across gene therapy pipelines and patient populations.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to its advanced research infrastructure, regulatory engagement, and patient advocacy ecosystem. The United States hosts the largest concentration of rare disease centers, registries, and clinical trial sponsors. FDA programs such as Orphan Drug Designation and Accelerated Approval are supporting innovation and market entry. Investment in genomic diagnostics and personalized medicine is driving platform expansion. Presence of leading biotech firms and academic institutions is reinforcing leadership.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR as healthcare modernization, genomics investment, and policy reform converge. Countries like China, India, Japan, and South Korea are scaling rare disease diagnostics and therapy access across urban and rural regions. Government-backed programs are supporting newborn screening, patient registries, and local manufacturing. Regional biotech firms are launching gene therapies and biologics tailored to population-specific indications. Demand for affordable and scalable solutions is rising across public and private healthcare systems. These trends are accelerating regional growth across rare disease treatment ecosystems.

Key players in the market

Some of the key players in Rare Disease Treatment Market include Biogen Inc., Vertex Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Amgen Inc., Takeda Pharmaceutical Company Ltd., Roche Holding AG, Regeneron Pharmaceuticals Inc., Ultragenyx Pharmaceutical Inc., Sarepta Therapeutics Inc., Alnylam Pharmaceuticals Inc., Bluebird Bio Inc. and BridgeBio Pharma Inc.

Key Developments:

In September 2025, Vertex reinforced its strategic diversification by expanding collaborations with CRISPR Therapeutics and other biotech firms to accelerate gene-editing therapies for sickle cell disease and beta thalassemia. These partnerships support the rollout of CASGEVY, Vertex's first FDA-approved gene-editing therapy, and broaden its rare disease pipeline beyond cystic fibrosis.

In March 2025, Biogen outlined expanded collaborations at the Stifel CNS Forum, focusing on rare diseases like lupus and spinal muscular atrophy. These partnerships aim to accelerate clinical development and balance portfolio risk, with strategic emphasis on high-impact neuroscience and immunology programs.

Drug Types Covered:

• Biologics
• Small Molecules
• Gene Therapies
• RNA-Based Therapies
• Cell Therapies
• Other Drug Types

Treatment Types Covered:

• Disease-Modifying Therapies
• Symptomatic Treatments
• Supportive Care
• Other Treatment Types

Route of Administrations Covered:

• Oral
• Injectable
• Inhalation
• Topical

Therapeutic Areas Covered:

• Oncology
• Neurology
• Hematology
• Metabolic Disorders
• Musculoskeletal Conditions
• Other Therapeutic Areas

Distribution Channels Covered:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Specialty Pharmacies

End Users Covered:

• Hospitals & Specialty Clinics
• Research & Academic Institutes
• Pharmaceutical & Biotech Companies
• Patient Advocacy Groups
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Rare Disease Treatment Market, By Drug Type

• 5.1 Introduction
• 5.2 Biologics
• 5.3 Small Molecules
• 5.4 Gene Therapies
• 5.5 RNA-Based Therapies
• 5.6 Cell Therapies
• 5.7 Other Drug Types

6 Global Rare Disease Treatment Market, By Treatment Type

• 6.1 Introduction
• 6.2 Disease-Modifying Therapies
• 6.3 Symptomatic Treatments
• 6.4 Supportive Care
• 6.5 Other Treatment Types

7 Global Rare Disease Treatment Market, By Route of Administration

• 7.1 Introduction
• 7.2 Oral
• 7.3 Injectable
• 7.4 Inhalation
• 7.5 Topical

8 Global Rare Disease Treatment Market, By Therapeutic Area

• 8.1 Introduction
• 8.2 Oncology
• 8.3 Neurology
• 8.4 Hematology
• 8.5 Metabolic Disorders
• 8.6 Musculoskeletal Conditions
• 8.7 Other Therapeutic Areas

9 Global Rare Disease Treatment Market, By Distribution Channel

• 9.1 Introduction
• 9.2 Hospital Pharmacies
• 9.3 Retail Pharmacies
• 9.4 Online Pharmacies
• 9.5 Specialty Pharmacies

10 Global Rare Disease Treatment Market, By End User

• 10.1 Introduction
• 10.2 Hospitals & Specialty Clinics
• 10.3 Research & Academic Institutes
• 10.4 Pharmaceutical & Biotech Companies
• 10.5 Patient Advocacy Groups
• 10.6 Other End Users

11 Global Rare Disease Treatment Market, By Geography

• 11.1 Introduction
• 11.2 North America
  • 11.2.1 US
  • 11.2.2 Canada
  • 11.2.3 Mexico
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 Italy
  • 11.3.4 France
  • 11.3.5 Spain
  • 11.3.6 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 New Zealand
  • 11.4.6 South Korea
  • 11.4.7 Rest of Asia Pacific
• 11.5 South America
  • 11.5.1 Argentina
  • 11.5.2 Brazil
  • 11.5.3 Chile
  • 11.5.4 Rest of South America
• 11.6 Middle East & Africa
  • 11.6.1 Saudi Arabia
  • 11.6.2 UAE
  • 11.6.3 Qatar
  • 11.6.4 South Africa
  • 11.6.5 Rest of Middle East & Africa

12 Key Developments

• 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 12.2 Acquisitions & Mergers
• 12.3 New Product Launch
• 12.4 Expansions
• 12.5 Other Key Strategies

13 Company Profiling

• 13.1 Biogen Inc.
• 13.2 Vertex Pharmaceuticals Inc.
• 13.3 Alexion Pharmaceuticals Inc.
• 13.4 Novartis AG
• 13.5 Pfizer Inc.
• 13.6 Sanofi S.A.
• 13.7 Amgen Inc.
• 13.8 Takeda Pharmaceutical Company Ltd.
• 13.9 Roche Holding AG
• 13.10 Regeneron Pharmaceuticals Inc.
• 13.11 Ultragenyx Pharmaceutical Inc.
• 13.12 Sarepta Therapeutics Inc.
• 13.13 Alnylam Pharmaceuticals Inc.
• 13.14 Bluebird Bio Inc.
• 13.15 BridgeBio Pharma Inc.